source
- AstraZeneca invests $2 billion in Summit Therapeutics to fund Phase 3 trials of ivonescimabAstraZeneca has agreed to a $2 billion all‑stock investment in Summit Therapeutics. The deal involves the purchase of preferred shares that can be converted into common stock, but it does not inclu…
- Novo Nordisk signs $2.6 billion deal with China's Hengrui for oral GLP-1/GIP candidateNovo Nordisk announced a licensing agreement with Chinese drugmaker Hengrui Pharmaceuticals, paying $300 million upfront for rights to a preclinical GLP-1/GIP dual-receptor agonist. The candidate,…